about
Drugging MYCN through an allosteric transition in Aurora kinase AStrategically targeting MYC in cancerRegulation of MYC gene expression by aberrant Wnt/β-catenin signaling in colorectal cancerMelanoma: from mutations to medicineSmall-molecule inhibitors of the Myc oncoproteinSolution Structure of a 2:1 Quindoline–c-MYC G-Quadruplex: Insights into G-Quadruplex-Interactive Small Molecule Drug DesignIdentification of cytotoxic drugs that selectively target tumor cells with MYC overexpressionInhibitor of MYC identified in a Kröhnke pyridine libraryMYC on the path to cancerDirect inhibition of c-Myc-Max heterodimers by celastrol and celastrol-inspired triterpenoids.10058-F4, a c-Myc inhibitor, markedly increases valproic acid-induced cell death in Jurkat and CCRF-CEM T-lymphoblastic leukemia cells.Myc-induced SUMOylation is a therapeutic vulnerability for B-cell lymphoma.Targeting protein-protein interactions as an anticancer strategyHumanized c-Myc mouseTargeting the mRNA-binding protein HuR impairs malignant characteristics of pancreatic ductal adenocarcinoma cellsIn vivo quantification and perturbation of Myc-Max interactions and the impact on oncogenic potential.Critical role of Shp2 in tumor growth involving regulation of c-MycTargeting c-MYC with T-cellsPten mediates Myc oncogene dependence in a conditional zebrafish model of T cell acute lymphoblastic leukemia.Targeting of the MYCN protein with small molecule c-MYC inhibitorsPerturbation of the c-Myc-Max protein-protein interaction via synthetic α-helix mimetics.Reversible linkage of two distinct small molecule inhibitors of Myc generates a dimeric inhibitor with improved potency that is active in myc over-expressing cancer cell lines.The c-Myc-LDHA axis positively regulates aerobic glycolysis and promotes tumor progression in pancreatic cancer.microRNA-206 impairs c-Myc-driven cancer in a synthetic lethal manner by directly inhibiting MAP3K13.Structurally diverse c-Myc inhibitors share a common mechanism of action involving ATP depletion.Potential effect of spliceosome inhibition in small cell lung cancer irrespective of the MYC statusStrategies to Inhibit Myc and Their Clinical ApplicabilityA framework for identification of actionable cancer genome dependencies in small cell lung cancer.Hyperglycemia-induced metabolic compensation inhibits metformin sensitivity in ovarian cancerBPTF is required for c-MYC transcriptional activity and in vivo tumorigenesis.Harnessing synthetic lethal interactions in anticancer drug discoveryMYC inhibition induces metabolic changes leading to accumulation of lipid droplets in tumor cellsMyc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancersGamabufotalin triggers c-Myc degradation via induction of WWP2 in multiple myeloma cells.MicroRNA-based screens for synthetic lethal interactions with c-MycNeuroblastoma treatment in the post-genomic era.PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression.MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4.Enigmatic MYC Conducts an Unfolding Systems Biology Symphony.Antagonism between FOXO and MYC Regulates Cellular Powerhouse.
P2860
Q24303381-D465B2F2-8BA1-4A41-B11C-68DE48998B62Q26747745-769A7FF0-B252-4E7E-A634-B131ED843E19Q26775423-B70918B5-0D90-446B-B823-12725CE8AC72Q27024061-553C3DCF-F6D6-4E70-806A-23E289B4A251Q27025648-47D2AE38-420C-4548-BB3B-EE96022C0CB6Q27674707-1D4179A0-F876-4273-9A8F-6E9519EA8E68Q28478132-6EE7E535-AA54-496B-BE55-8FB2011F60C5Q28656132-B9E0AE1C-971E-41EF-9247-138809385742Q29619979-745AEA7C-DA29-4EB7-B44D-25E0CDF076D3Q30278518-316DC41D-0F66-421D-8E97-D1B32CF8FA28Q33967429-228AF667-9680-4077-9665-8995E7A77C42Q34293007-4F9D26A9-6FF5-4608-A07A-E749EBE5AA4FQ34347892-46B89360-EBC7-4C3B-804D-97758645B005Q34364444-AD8AC8D7-97DA-4756-82E0-B19AE8A7BFA4Q34491276-ADF08085-5C64-4681-962E-3E4CD602D247Q34619131-35BE34DE-D557-4F71-97FC-E2940E9CD43AQ34713949-6472C06C-EC58-4E38-8D74-177F96ACD113Q35018846-8CE17DE1-8BE3-4D4A-A46C-B0AFD8C203B8Q35144582-BCA0B4FF-77F2-4048-B361-02E3BFC196EEQ35173570-D7A64373-E88A-4D67-ACFB-6973DDAE52AEQ35570730-606780AD-050E-4BE7-88EE-DB318129B579Q35601876-32286AEC-D628-4B49-BBB9-0F59BD86A83AQ35674347-66EC543D-6407-48EF-9725-D91FFA3B58C4Q35937111-F413C1C9-0B9A-4FF5-9ED9-1C7BE7886B54Q36140644-66ACCD39-E140-4B56-9256-4761BDDE8656Q36278557-D0778267-1A5C-4387-9A26-B6310C8C7F42Q36303678-05C6E68E-A2C2-4347-B3F7-E823FC6C5503Q36342432-2334589C-5CAF-4536-9230-3847CD0DE550Q36414231-0B4E0A1E-C5D0-4EA4-BDCC-9D5C4CCB5B98Q36506766-CF5F9B23-2345-47FC-B403-8D12054B53FCQ36839571-5922CF9C-8D9C-4D27-B13F-CE917DB19DEFQ36950291-E01637BA-A73A-4B98-8972-6286AB1412E4Q37031640-18A2FAAE-EEC4-4919-A88E-C1D033A83A42Q37085867-3C7FBE97-EDB0-4B88-A8B5-FC723BA569CBQ37495218-9005F263-8197-4E7F-A12A-36728650E125Q37633731-C5DE0A99-C907-4E6B-BF5B-DBFAFDF52F83Q37686796-74B6DA1D-DF44-4EE7-9734-A4764985E4E7Q37688166-DD3B2DCE-14AB-4704-9371-14D7DDFA46FCQ37827073-BDF65606-02EC-414C-B5CD-90F99D533EFDQ38102998-DB2699D6-81A5-4925-A3CD-62CC1F32363D
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Therapeutic Targeting of Myc.
@ast
Therapeutic Targeting of Myc.
@en
Therapeutic Targeting of Myc.
@nl
type
label
Therapeutic Targeting of Myc.
@ast
Therapeutic Targeting of Myc.
@en
Therapeutic Targeting of Myc.
@nl
prefLabel
Therapeutic Targeting of Myc.
@ast
Therapeutic Targeting of Myc.
@en
Therapeutic Targeting of Myc.
@nl
P2860
P356
P1433
P1476
Therapeutic Targeting of Myc.
@en
P2093
Edward V Prochownik
P2860
P304
P356
10.1177/1947601910377494
P50
P577
2010-06-01T00:00:00Z